E. Pedrol

发表

Short communication: HIV infection, antiretrovirals, and apoptosis: studies on skeletal muscle.

Ò. Miró, J. Gatell, E. Martinez, 2005, AIDS research and human retroviruses.

Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status

A. Del Arco, E. Ribera, J. Pérez-Molina, 2011, HIV clinical trials.

Mitochondrial Effects of Antiretroviral Therapies in Asymptomatic Patients

Ò. Miró, J. Gatell, B. Rodríguez-Santiago, 2004, Antiviral therapy.

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

E. Ribera, J. Pérez-Molina, Jesús Santos, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

D. Podzamczer, B. Clotet, J. Gatell, 2009, Journal of acquired immune deficiency syndromes.

Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort.

F. Vidal, E. Ribera, J. Cosín, 2010, Enfermedades Infecciosas y Microbiologia Clinica.

Spanish HIV-1-Infected Long-Term Nonprogressors of More Than 15 Years Have an Increased Frequency of the CX3CR1 249I Variant Allele

S. Mallal, C. Gutiérrez, C. Richart, 2005, Journal of acquired immune deficiency syndromes.

Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward.

R. Estruch, A. Castells, R. Marrades, 1991, Scandinavian journal of gastroenterology.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

J. Miro, J. Gatell, J. Mallolas, 2007, Revista clinica espanola.

Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases.

Ò. Miró, M. García-Carrasco, J. Grau, 1996, Seminars in arthritis and rheumatism.

Lack of Association of SDF-1 3′A Variant Allele With Long-Term Nonprogressive HIV-1 Infection Is Extended Beyond 16 Years

C. Gutiérrez, C. Richart, M. Broch, 2005, Journal of acquired immune deficiency syndromes.

Effect of Genetic Variants of CCR2 and CCL2 on the Natural History of HIV-1 Infection: CCL2-2518GG Is Overrepresented in a Cohort of Spanish HIV-1-Infected Subjects

Felipe García, M. Plana, J. Gatell, 2007, Journal of acquired immune deficiency syndromes.

Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.

B. Clotet, E. Negredo, E. Ribera, 2009, The Journal of antimicrobial chemotherapy.

Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort

J. Cosín, M. Fuentes-Ferrer, P. Viciana, 2011, BMC women's health.

B. Clotet, E. Negredo, R. Lopez-Blazquez, 2010, Antiviral research.

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

J. Olalla, M. Riera, F. Pulido, 2015, HIV clinical trials.

Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals.

Ò. Miró, J. Gatell, E. Martinez, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Upregulatory Mechanisms Compensate for Mitochondrial DNA Depletion in Asymptomatic Individuals Receiving Stavudine Plus Didanosine

Ò. Miró, J. Gatell, E. Martinez, 2004, Journal of acquired immune deficiency syndromes.

[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].

E. Martinez, S. Johnston, F. Pulido, 2006, Enfermedades infecciosas y microbiologia clinica.

Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years

C. Gutiérrez, C. Richart, M. Broch, 2006, Journal of acquired immune deficiency syndromes.

Skeletal muscle studies in patients with HIV-related wasting syndrome

Ò. Miró, J. Mallolas, J. Grau, 1997, Journal of the Neurological Sciences.

Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM).

B. Coll-Vinent, J. Grau, M. Cid, 1996, Clinical and experimental immunology.

Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement.

Ò. Miró, J. Grau, C. Herrero, 1996, The Journal of rheumatology.

Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy.

J. Miro, J. Gatell, J. Mercader, 1990, AIDS.

Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study

D. Podzamczer, V. Falcó, E. Pedrol, 2008, Journal of acquired immune deficiency syndromes.

Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.

Ò. Miró, J. Gatell, E. Martinez, 2015, The Journal of antimicrobial chemotherapy.

Genetic and Functional Mitochondrial Assessment of HIV-Infected Patients Developing HAART-Related Hyperlactatemia

F. Villarroya, Ò. Miró, E. Negredo, 2009, Journal of acquired immune deficiency syndromes.

Metabolic and Mitochondrial Effects of Switching Antiretroviral-Experienced Patients to Enfuvirtide, Tenofovir and Saquinavir/Ritonavir

Ò. Miró, S. López, G. Garrabou, 2005, Antiviral therapy.

Mitochondrial Dna Depletion and Respiratory Chain Enzyme Deficiencies are Present in Peripheral Blood Mononuclear Cells of HIV-Infected Patients with Haart-Related Lipodystrophy

Ò. Miró, J. Gatell, B. Rodríguez-Santiago, 2002, Antiviral therapy.

Human immunodeficiency virus type 1 infections and myopathy: Clicical relevance of zidovudine therapy

Josep Maria Salanova Grau, J. Fernandez-Solà, E. Pedrol, 1993, Annals of neurology.

Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

D. Podzamczer, E. Negredo, J. Pineda, 2009, Journal of acquired immune deficiency syndromes.

The relationship between antiretroviral prescription patterns and treatment guidelines in treatment‐naïve HIV‐1‐infected patients

E. Ribera, J. Cosín, P. Viciana, 2009, HIV medicine.

High Sensitivity C-Reactive Protein and Response to Highly Active Antiretroviral Therapy in Women with HIV-1 Infection

C. Richart, M. Broch, F. Vidal, 2006, Journal of acquired immune deficiency syndromes.

Cerebral paradoxical embolism in a patient infected by human immunodeficiency virus; TO THE EDITOR

Ò. Miró, E. Pedrol, F. Cardellach, 1996, European journal of neurology.

[Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study].

P. Viciana, E. Pedrol, J. Pasquau, 2014, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.

F. Vidal, E. Ribera, M. Crespo, 2008, The Journal of antimicrobial chemotherapy.

Patients’ Perception and Effectiveness of a Treatment Containing Enfuvirtide When Used in HIV-Infected Patients Without Very Advanced Disease

F. Pulido, M. Fernández-Guerrero, E. Pedrol, 2008, HIV clinical trials.

Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study

J. Olalla, J. Blanco, M. Riera, 2013 .

Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.

J. Mallolas, E. Ferrer, E. Pedrol, 2012, AIDS research and human retroviruses.

Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.

R. Paredes, B. Clotet, J. Puig, 2006, AIDS research and human retroviruses.

Visual impairment in a woman with histiocytosis.

E. Pedrol, A. Coca, A. Urbano-Márquez, 1995, Postgraduate medical journal.

Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral Therapy.

Streptococcal myositis as a complication of juvenile dermatomyositis

Felipe García, J. Grau, C. Herrero, 1991, Neuromuscular Disorders.

Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy.

Ò. Miró, V. Nunes, E. Pedrol, 2000, AIDS.

In Vivo Effects of Highly Active Antiretroviral Therapies Containing the Protease Inhibitor Nelfinavir on Mitochondrially Driven Apoptosis

F. Villarroya, Ò. Miró, J. Gatell, 2005, Antiviral therapy.

Efficacy and Safety of Once-Daily Combination Therapy with Didanosine, Lamivudine and Nevirapine in Antiretroviral-Naive HIV-Infected Patients

J. Miro, J. Blanco, I. Ocaña, 2005, Antiviral therapy.

Josamycin-induced pedal oedema.

X. Bosch, E. Pedrol, A. Urbano-Márquez, 1993, British medical journal.

[A tuberculotic subcutaneous abscess as the form of presentation of the acquired immunodeficiency syndrome].

J. Grau, E. Pedrol, J. Casademont, 1993, Revista clinica espanola.

Herpetiform and mollusca contagiosa‐like cutaneous cryptoccosis in a patient with AIDS

M. Lecha, E. Pedrol, J. Mensa, 1989, The British journal of dermatology.

Polyarteritis nodosa in human immunodeficiency virus infection: report of four cases and review of the literature.

Ò. Miró, B. Coll-Vinent, C. Font, 1996, British journal of rheumatology.

Clinical, histological and molecular reversibility of zidovudine myopathy

Ò. Miró, J. Grau, E. Pedrol, 1998, Journal of the Neurological Sciences.

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

Ò. Miró, Virginia Nunes, E. Pedrol, 2001, AIDS.

The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction.

X. Estivill, J. Grau, A. Barrientos, 1996, Brain : a journal of neurology.

Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach

B. Clotet, L. Ruiz, E. Negredo, 2003, Antiviral therapy.

A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)

D. Podzamczer, X. Badia, J. Miro, 2001, Antiviral therapy.

Lack of muscle toxicity with didanosine (ddI) Clinical and experimental studies

Josep Maria Salanova Grau, J. Fernandez-Solà, E. Pedrol, 1996, Journal of the Neurological Sciences.

[A comparative study of the clinical and histological characteristics between classic nemaline myopathy and that associated with the human immunodeficiency virus].

Ò. Miró, J. Mallolas, M. García-Carrasco, 1995, Medicina clinica.

Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers.

J. Fernandez-Solà, J. Grau, M. Cid, 1995, Clinical neuropathology.

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

D. Podzamczer, J. Gatell, E. Martinez, 2007, AIDS.

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study

A. Curran, E. Pedrol, O. Martínez-Madrid, 2015, HIV medicine.

Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients

Ò. Miró, A. León, J. Mallolas, 2020, Frontiers in Genetics.

[Cerebral vascular complications in Conn's disease: report of two cases].

Ò. Miró, J. Grau, E. Pedrol, 1995, Neurologia.

Effect of TNF-α genetic variants and CCR5Δ32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards

Felipe García, M. Plana, A. León, 2010, BMC Medical Genetics.

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

D. Podzamczer, J. Gatell, E. Martinez, 2003, The New England journal of medicine.

Polyarteritis nodosa confined to calf muscles.

J. Grau, M. Cid, E. Pedrol, 1992, The Journal of rheumatology.

[Toxic megacolon and intestinal perforation caused by Salmonella enteritidis].

A. Castells, E. Pedrol, J. Casademont, 1990, Revista clinica espanola.

[Wegener's granulomatosis in the elderly].

E. Pedrol, F. Cardellach, S. López-Coll, 1996, Anales de medicina interna.

Adult-onset mitochondrial myopathy.

J. Fernandez-Solà, J. Grau, F. Graus, 1992, Postgraduate medical journal.

Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral therapy.

Simplified Therapy with Zidovudine, Lamivudine, and Abacavir for Very Nonadherent, Treatment-Failing Patients

E. Pedrol, H. Knobel, A. Carmona, 2004, HIV clinical trials.

Chronic fatigue syndrome: studies on skeletal muscle.

J. Fernandez-Solà, J. Grau, E. Pedrol, 1992, Clinical neuropathology.

Physical Activity Associated with HIV

E. Pedrol, R. Ramírez, S. Ruiz, 2012 .

D. Podzamczer, X. Badia, J. Gatell, 2004, HIV clinical trials.

[Reasons for the introduction of darunavir in the antirretroviral treatment in HIV-infected patients].

E. Pedrol, S. Ruiz, Juan Carlos López-Bernaldo, 2013, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors.

Esteban Martínez, Francesc Villarroya, Enric Pedrol, 2007, Current HIV research.

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia].

Ò. Miró, S. Nogué, E. Pedrol, 1996, Medicina clínica (Ed. impresa).

Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral therapy.

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults

J. Gatell, J. Mallolas, F. Vidal, 2008, AIDS.

[Palinopsia as a manifestation of migraine associated with other symptoms].

Ò. Miró, E. Pedrol, F. Cardellach, 1995, Medicina clinica.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48‐week analysis of results from the PROTEST study

R. Paredes, D. Podzamczer, E. Poveda, 2017, HIV medicine.

[Acute pancreatitis caused by demeclocycline].

E. Pedrol, J. Martos, R. Célis, 1989, Revista clinica espanola.

Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.

J. Olalla, J. Blanco, M. Riera, 2013, HIV Clinical Trials.

Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.

F. Vidal, E. Ribera, M. Crespo, 2008, The Journal of antimicrobial chemotherapy.

[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus].

E. Negredo, F. Lozano, R. Palacios, 2015, Enfermedades infecciosas y microbiologia clinica.

Symptomatic myopathies in HIV-1 infected patients untreated with antiretroviral agents--a clinico-pathological study of 30 consecutive patients.

Ò. Miró, B. Coll-Vinent, E. Pedrol, 1996, Clinical neuropathology.

Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.

F. Vidal, G. Jm, J. Peraire, 2015, The Journal of antimicrobial chemotherapy.

[Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions].

P. Arazo, E. Pedrol, J. Flores, 2007, Medicina clinica.